Qingfeng Pharmaceutical Group   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Ganzhou China (1976)

Organization Overview

First Clinical Trial
2010
NCT01554930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 4)

Breast Neoplasms (Phase 2)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Carcinoma, Ovarian Epithelial (Phase 2)

Dyspepsia (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Peritonsillar Abscess (Phase 4)

Pneumonia (Phase 4)

Prostatic Neoplasms (Phase 2)

Tonsillitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 24